Cannara Biotech, Inc. · TSX:LOVE
Cannara Biotech — Q4 2025 Earnings Presentation
24 slides from Cannara Biotech's earnings presentation, October 2025
Slide 1: Premium-Quality Cannabis at Scale
TSXV: LOVE | OTCQB: LOVFF | FRA: 8CB0 PREMIUM-QUALITY CANNABIS AT SCALE INVESTOR DECK Q4 AND FISCAL YEAR 2025 (AS OF AUGUST 31, 2025)
Slide 2: General Disclosures
General Disclosures Disclaimer This presentation is qualified in its entirety by reference to, and must be read in conjunction with, the information contained in the Company’s most recent Annual Information Form, as well as in the Company’s most recent consolidated financial statements, together wit
Slide 3: General Disclosures: Forward-Looking Statements
General Disclosures Forward-Looking Statements This presentation may contain “forward-looking information” within the meaning of Canadian securities legislation (“forward-looking statements”). These forward-looking statements are made as of the date of this presentation and the Company does not inte
Slide 4: An Emerging Leader In Canada
An Emerging Leader In Canada Vertically-integrated Licensed Producer of premium-grade cannabis products Canada’s 7th Top LP by sales1 Total owned production capacity up to 100,000 kg annually: • Activated rooms 11 + 12 (of 24) at Valleyfield, raising planned capacity to 39,500 kg Overview Performanc
Slide 5: Sustained Profitability Sets Us Apart
Sustained Profitability Sets Us Apart FY 2025 % Increase FY 2024 FY 2023 $107.3M 31% $82.2M $57.6M $44.5M 59% $27.9M $21.1M Overview Performance 41% 21% 34% 37% Assets Strategy $28.1M 86% $15.1M $13.7M Leadership Summary 26% 44% 18% 24% $13.1M 105% $6.4M $6.9M $20.0M 87% $10.7M $5.9M $13.7M 328% $3.
Slide 6: Sustained Profitability Sets Us Apart
Sustained Profitability Sets Us Apart Fiscal Year Ended August 2025 Q4 Q3 Q2 Q1 $28.3M $27.3M $26.6M $25.1M $11.8M $12.1M $10.8M $9.8M Overview Performance Assets 42% 44% 41% 39% Strategy Leadership $7.5M $7.6M $7.1M $6M Summary 26% 28% 27% 24% $3.3M $4.1M $3.3M $2.3M $2.8M $13.9M ($2.6M) $5.8M $1.4
Slide 7: Well Capitalized Balance Sheet
Well Capitalized Balance Sheet Selected Financial Highlights August 31, 2025 August 31, 2024 August 31, 2023 Cash $14.4 M $6.6 M $4.3 M Accounts receivable $14.1 M $13. M $10.6 M Biological assets $6.8 M $6.6 M $5.8 M Inventory $44.5 M $33.4 M $28. M Working capital1 $48. M $40.5 M $30.5 M Overview
Slide 8: Increasing Our Market Share
Increasing Our Market Share Estimated Retail Market Growth FY2025 vs FY2024 Province FY 2025 FY 2024 % Increase QC 12.7% 8.3% 53% ON 2.8% 2.7% 4% AB 2.5% 1.9% 32% Overview BC 1.6% 1.1% 45% Performance SK 1.4% 1.1% 27% Assets MB 0.8% 0.2% 300% Strategy Leadership NS 0.5% 0.05% 900% Summary National 3
Slide 9: National Estimated Retail Sales Growth
National Estimated Retail Sales Growth FY2025 FY2025 FY2024 Licensed Producer $ YoY Δ % YoY Δ National Sales Rank Total Retail Sales Total Retail Sales 1 Organigram $667.2M $621.5M $40.M 7% 2 Tilray $522.5M $595.4M -$74.4M -12% 3 Auxly Cannabis $337.8M $247.2M $89.9M 37% 4 Village Farms $351.2M $406
Slide 10: Canadian Recreational Cannabis Market
Canadian Recreational Cannabis Market 2ND Largest Cannabis Market in the world Legal Cannabis Market expected to Monthly Retail Sales of Legal reach Cannabis Stores in Canada from ~$9.81 billion CDN (US$6.58 B) by 20291 October 2018 to October 20252 7 Retail sales in million CDN dollars Overview 6 5
Slide 11: Two Quebec Based Mega Facilities: Valleyfield
Two Quebec Based Mega Facilities Valleyfield: 1M sq. ft., 24 independent grow rooms, each 25,000 sq. ft. Overview Performance Assets Strategy Leadership Summary Each activated zone has been designed to replicate indoor growing conditions eliminating variability and maximizing Valleyfield Facility qu
Slide 12: Two Quebec Based Mega Facilities: Farnham
Two Quebec Based Mega Facilities Farnham: 625,000 sq. ft., 170, 000 sq. ft. of cannabis operations Overview Performance Assets Strategy Leadership Summary Farnham Facility • 625,000 sq. ft. facility provides 170,000 sq. ft. of cannabis operation. • R&D Facility (Pheno-hunting, Tissue Culture and Reg
Slide 13: Scaling Sales
Scaling Sales Cannabis Revenue Growth Trajectory as Valleyfield Production Scales Up Cannabis NET Revenue in $ Millions Gross Profit Before Fair Value Adjustment % Gross Margin $28.3 100% $27.3 $26.6 90% $24.0 Overview 80% $22.1 Performance 70% Assets $18.5 $18.8 $18.3 Strategy $17.2 60% Leadership
Slide 14: Disciplined Growth & Expansion
Disciplined Growth & Expansion Cannara’s Estimated Fiscal Year End Production Capacity in kg 120,000 100000 100,000 Annualized Production (kg) 88,000 Overview 80,000 75,000 Performance Assets 65,000 Strategy 60,000 Leadership 50,000 50,000 Summary 40,000 30,500 33,500 Total owned potential productio
Slide 15: Why Quebec
Why Quebec Average Electricity Rates By Province In Cents Per Kw Hour Quebec has the lowest electricity rates in Canada QC MB BC ON SK NS AB 5.9¢/kWh 6.0¢/kWh 7.4¢/kWh 10.3¢/kWh 11.1¢/kWh 11.6¢/kWh 14.1¢/kWh Overview Performance Assets Quebec has the highest barriers Strategy 578 510 282 151 of entr
Slide 16: Competitive Advantage
Competitive Advantage Scalable Quality Innovation in Products & Genetics • Deliver true to craft like procedures including hang drying and • Diverse portfolio of products: dried flower, pre-rolls, hand trimming cannabis to ensure quality. infused pre-rolls, milled flower, vapes, edibles, hash and •
Slide 17: Delivering Premium Quality Cannabis
Delivering Premium Quality Cannabis Focusing on high cannabinoid content and rich flavourful cannabis Our cannabis is grown using Rare genetics Hang dried & slow cured methods inspired by the most sophisticated markets in the Overview world: Performance Assets Strategy Leadership Summary Quality Acc
Slide 18: Portfolio of Brands
Portfolio of Brands Overview Performance Assets Strategy Leadership Summary Q4 FY2025 18
Slide 19: Cannara Strategy
Cannara Strategy Delivering a premium-quality product at scale and at lower prices for consumers is at the heart of our strategy Purposeful growth by focusing on the Canadian legal market that is expected to reach ~$9.81 billion CDN (US$6.58 B) by 20291 Overview Respond to market demand by increasin
Slide 20: Capital Structure
Capital Structure As at Oct 3, 2025 As at August 31, 2025 As at August 31, 2024 As at August 31, 2023 91.4M 90.0M 87.7M Overview Average Estimated Market Capitalization Last 30 Days Performance $160M Assets Strategy Leadership Summary Average Closing Share Price Last 30 Days $1.69 >50% Current insid
Slide 21: Executive Leadership Team
Executive Leadership Team Zohar is an entrepreneur who has Nicholas Sosiak, CPA, is the Avi has been in the information launched several successful businesses. dynamic and hands-on CFO technology industry for over 20 He has founded, advised and invested of Cannara Biotech, years. He specializes in i
Slide 22: Executive Leadership Team
Executive Leadership Team ZOHAR KRIVOROT DONALD OLDS CHAIRMAN & CEO LEAD DIRECTOR & CHAIRMAN OF THE AUDIT, Zohar is a seasoned entrepreneur who has built & GOVERNANCE COMMITTEE and grown multiple successful businesses. He has Donald Olds is an experienced life played pivotal roles as a founder, advi
Slide 23: In Summary – Winning in Canada
In Summary – Winning in Canada Well capitalized, fast-growing business Operating with strong margins and with an established history of execution achieving positive EBITDA, Net income, cash flow and profitability Offering customers the highest value Overview products at disruptive low prices Perform
Slide 24: Thank You
TSXV: LOVE | OTCQB: LOVFF | FRA: 8CB0 THANK YOU Overview Performance www.cannara.ca Assets Strategy investors.cannara.ca Leadership Summary www.instagram.com/cannarabiotech www.facebook.com/cannarabiotech CANNARA HEADQUARTERS FARNHAM FACILITY VALLEYFIELD FACILITY 333 Decarie blvd, Suite 200 1144 Bou